Irsogladine

Last updated
Irsogladine
Irsogladine.svg
Names
Preferred IUPAC name
6-(2,5-Dichlorophenyl)1,3,5-triazine-2,4-diamine
Other names
DCPDAT, Dicloguamine, MN-1695.
Identifiers
ChemSpider
PubChem CID
UNII
Properties
C9H7Cl2N5
Molar mass 256.09 g·mol−1
Pharmacology
A02BX16 ( WHO )
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Irsogladine is a phosphodiesterase inhibitor. [1]

Synthesis

ChemDrug Synthesis: Patent: Irsogladine synthesis.svg
ChemDrug Synthesis: Patent:

2,4-Dichloro-6-(2,5-dichlorophenyl)-1,3,5-triazine [61479-79-6] (1) (2) Dicyandiamide [461-58-5] (3) 2,5-Dichlorobenzonitrile [21663-61-6] (4)

References

  1. ↑ Satoh, H; Amagase, K; Takeuchi, K (2013). "Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats". The Journal of Pharmacology and Experimental Therapeutics. 348 (2): 227–35. doi:10.1124/jpet.113.208991. PMID   24254524. S2CID   23740642.
  2. ↑ Serradell, MN; Blancafort, P.; Castaer, J.; MN-1695. Drugs Fut 1983, 8, 6, 502.
  3. ↑ Ueda F, Aratani S, Mimura K, Kimura K, Nomura A, Enomoto H. Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals. Arzneimittelforschung. 1984;34(4):474-7. PMID: 654016.
  4. ↑ DE2506814 idem Hiromu Murai, 6 More », U.S. patent 3,966,728 (1976 to Nippon Shinyaku Co., Ltd.).


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.